FEB 2022

Carola Weiss joins InterAx Biotech AG as VP Business Development

February 2022, Switzerland

Today, InterAx Biotech is pleased to announce that Carola Weiss has joined the company as VP Business Development. Carola Weiss is a Senior Executive with more than 20 years of international experience in the biopharmaceutical industry.

Carola Weiss’ professional career brings deep expertise in business development, marketing & sales, licensing, alliance management, and strategic partnering. Her expertise guided numerous global negotiations, conclusions of partnership agreements, and fostered growth for her employers.

Experience and Outlook

The focus of Carola’s activities has been in pharmaceutical firms, including F. Hoffmann-La Roche and Actelion Pharmaceuticals Ltd. She joined Actelion as an early-stage company and excelled in business development with key projects in market assessment, product launches, line extensions, licensing deals, strategic partnerships, new market entries, and continuous improvement of marketing and sales. Carola’s responsibilities expanded with the organization’s growth until it was acquired in 2017 by Johnson & Johnson. After the acquisition she integrated the global partnership businesses into the Johnson & Johnson organizations. As an innovative and accomplished global leader focused on impact with long-standing biotechnology experience, Carola Weiss worked in local, regional, and global roles with a track record of creating high-performing teams. 

“We are delighted to officially welcome Carola Weiss as a new member of our management team” said Dr. Aurélien Rizk, CEO of InterAx Biotech. “Carola’s expertise, network and leadership will help to commercialize our unique discovery platform and lead drug candidate for triple-negative breast cancer”

InterAx unique technology for drug discovery has been successfully applied on three biopharma collaborations and one internal oncology drug discovery program. InterAx triple-negative breast cancer drug candidate shows excellent efficacy on cancer cell lines, good pharmacokinetic properties, and target engagement in-vivo. InterAx is now scaling up the commercialization of its platform and seeking a co-development partner for its drug candidate.

“I am excited to support InterAx in commercializing its groundbreaking platform to small, mid-sized and large drug companies to further improve speed and success rates in GPCR-related drug discovery. My role will be to continuously increase the number of mutually productive partnerships, allowing InterAx to position itself as a game changer in this most exciting class of drug targets.”, says Carola Weiss. 

InterAx Biotech AG

InterAx Biotech AG is pioneering computational pharmacology for drug discovery. The Swiss company developed a proprietary discovery platform to decipher and guide the optimization of intracellular pathways – one of the least understood black boxes in biology and a significant point of failure for new medicines. InterAx applies mathematical models and simulations to in-house derived bioanalytical data in order to address the complexity of drug-induced cellular signaling mechanisms and design new drugs for unmet medical needs. 

Printer friendly version.

SEP 2021

Early and successful completion of European Union’s H2020 Project 


September 2021, Switzerland


Today, InterAx Biotech AG, a Biotech company located in Villigen, Switzerland, has completed its two-year Horizon 2020-project “PICARD” successfully and four months in advance to the deadline. The newly developed drug discovery platform combines for the first time classical pharmacology, computational methods, systems biology and artificial intelligence to revolutionise drug discovery.

The European Union’s SME Instrument Horizon 2020 Project PICARD which started on October 1st 2019 was successfully completed by InterAx four months in advance on May 31st, 2021. With a total project volume of 2.49M EUR, InterAx expanded its drug discovery platform and boosted its commercialization efforts with the acquisition of three Pharma collaborations. With the integration of Artificial Intelligence, InterAx is now able to actively determine how to modify the chemistry of compounds to achieve specific cellular responses.

“I am very proud of the whole InterAx team for the successful achievement of the very ambitious goals set in our Picard H2020 project in such short time and with limited resources” explains Dr. Aurélien Rizk, CEO of InterAx Biotech. “The overall assessment of PICARD by the EU experts has been extremely good – the project has delivered exceptional results with significant immediate impact for the industry.”
InterAx has been pushing the boundaries of current knowledge and practice in cutting-edge technologies in an inherently interdisciplinary combination of analytical science, systems biology and machine learning. The ability to predict in vivo activity of novel chemical entities will lead to a reduction of animal testing, an increase of clinical trials success rate and a reduction of time to market for new treatments.

InterAx has established a platform that combines cell-based real-time assays and proprietary computational algorithms to enable intelligent drug candidate design targeting the largest class of drug targets (G Protein-Coupled Receptors, GPCRs) – which counts for more than 30% of all approved drugs.
The company applies mathematical models and simulations to in house-derived experimental data to address the complexity of drug-induced cellular signalling mechanisms. The technology offers outstanding potential to design new medicines that specifically activate the cellular response responsible for the desired therapeutic effect and reduce the cellular response responsible for adverse effects.

The company is currently focusing on further advancements of its technology platform and on in-house drug discovery of next-generation therapeutics for conditions with high unmet medical needs.
The InterAx discovery program to treat several solid tumors is showing promising results. First in class drug molecules with high affinity and potency on a novel target are under further investigation in animals after initial promising results in vitro to block proliferation and migration of breast cancer cells.
The target receptor is essential for the coordination of many physiological processes, in particular the immune cell behavior. Its deregulation is linked with many solid tumors, inflammatory diseases, and neurological diseases.


Printer friendly version.

APR 2021

InterAx Biotech further strengthens its Scientific Advisory Board – welcoming Prof. Dr. Ruedi Aebersold as a member


April 2021, Switzerland


Today, InterAx Biotech announced that Prof. Dr. Ruedi Aebersold has joined the company Scientific Advisory Board (SAB) as a member. InterAx is a privately held ETH Zurich and Paul Scherrer Institute spin- off reinventing drug discovery with systems biology and artificial intelligence to significantly reduce the time and costs associated with the discovery and development of new drugs for a wide array of human diseases.

Prof. Dr. Ruedi Aebersold is a pioneer in the field of proteomics and systems biology. He co-founded the Institute for Systems Biology in Seattle in 2000 – the first-ever institute dedicated to the study of relationships and interactions between various parts of biological systems. He serves on the Scientific Advisory Committees of numerous academic and private-sector research organizations. He received multiple prestigious honors and awards in his career, including being ranked #1 on the 2015 list of “most influential people in the analytical sciences” by the Analytical Scientist and most recently the 2020 Swiss Science Prize Marcel Benoist.

“We are honored to officially welcome Prof. Dr. Ruedi Aebersold as a new member of our Scientific Advisory Board,” said Dr. Aurélien Rizk, CEO of InterAx Biotech. “Dr. Aebersold’s expertise, insights and direction will provide an unmatched mentorship as the company is extending its core technology to predict a broader range of drug responses. This will be especially valuable as InterAx Biotech is entering a new phase – advancing its in-house programs driven by its proprietary technology platform.”
“It is exciting to support a company successfully pioneering the commercialization of mathematical modeling and principles for systems biology-based drug discovery that have been developed in academia in the last decades.” says Prof. Dr. Ruedi Aebersold.

The InterAx Scientific Advisory Board consists of 7 members and includes experts in GPCR pharmacology, computational and structural biology, machine learning, medicinal chemistry, translational medicine in oncology and immunology. These experts provide scientific advice and are involved in strategic discussions about the company’s direction. The main focus is on the advancement of the InterAx technology platform and on the in-house drug discovery of next-generation therapeutics for conditions with highly unmet medical needs.

After having succeeded in acquiring first Pharma and Biotech partners and in securing EUR 2.49M European grant (Grant agreement No 880322), InterAx Biotech is looking forward to further expand its partner base and develop its in-house oncology program. InterAx is planning to grow further and is celebrating its 5-year anniversary with the opening of a new investment round.

Printer friendly version.